Actively Recruiting
Redefining BMI: The Body, Mind, and Inflammation Trial
Led by Virginia Commonwealth University · Updated on 2026-05-06
32
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
Sponsors
V
Virginia Commonwealth University
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Emerging adulthood (18-25 years of age) is a critical developmental window to promote weight management and cardiometabolic health, particularly for emerging adult women. The primary purpose of this study is to test the preliminary efficacy of the intensive lifestyle intervention for EA women in reducing adiposity, as well as improving biomarkers of inflammation and metabolic risk over 12 months compared with a traditional behavioral weight loss intervention. This treatment program will be tested in emerging adult (EA) women ages 18-25 years old with a BMI of 25-50 kg/m\^2.
CONDITIONS
Official Title
Redefining BMI: The Body, Mind, and Inflammation Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ages 18-25 years
- Body mass index (BMI) 25-50 kg/m²
- Female
You will not qualify if you...
- Currently pregnant or lactating
- Currently involved in a weight loss program or using weight loss medication
- Lost more than 5% of body weight in the past 3 months
- Uncontrolled medical conditions posing safety risks with diet or physical activity
- Diagnosis of type 1 or type 2 diabetes or impaired fasting blood glucose
- Rheumatologic or gastrointestinal conditions causing severe systemic inflammation
- Medical conditions affecting the hypothalamic-pituitary-adrenal axis
- History of heart conditions, chest pain, or loss of consciousness
- Use of medications impacting weight or metabolism within past 3 months
- Use of anti-inflammatory medications within past 3 months
- Diagnosis or history of Anorexia Nervosa or Bulimia Nervosa or compensatory behaviors in past 3 months
- Hospitalization for depression or psychiatric disorder within past 12 months
- Uncontrolled bipolar or psychotic disorder
- Current suicidal intent
- Planning to move away during the study period
- Unwillingness to be randomized to either study group
- Unable to read and speak English
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Virginia Commonwealth Universtity
Richmond, Virginia, United States, 23298
Actively Recruiting
Research Team
V
Vivian Hunter
CONTACT
J
Jessica LaRose
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here